Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06605378 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease

StatusRecruiting
PhaseNot specified
SponsorEnsoma
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Jun 2026 → Dec 2026
See other at-risk trials from Ensoma

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion pushed from Jun 2026 to Dec 2026v10
  2. Primary and study completion dates: Dec 2025 to Jun 2026v9
  3. Primary and study completion dates: Sep 2025 to Dec 2025v8
  4. Primary and study completion dates: Mar 2025 to Sep 2025
    • Site details revised at 2 of 52 sites
    v7
  5. Eligibility criteria expanded, about 68 words
    • Site contacts updated at 1 of 52 sites
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 51 to 52
    • Primary and study completion dates: Jan 2025 to Mar 2025
    • Eligibility criteria shortened, about 6 words
    v5
  2. Study sites: 50 to 51v4
  3. Study sites: 49 to 50
    • Start date changed from estimate of Oct 1, 2024 to Nov 18, 2024
    v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 2 to 49
    • Start date: Sep 30, 2024 to Oct 1, 2024
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Ensoma
2 trials monitored
See 1 trial at risk
This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.
Trial Details
NCT Number NCT06605378
Lead Sponsor Ensoma
Conditions
(from sponsor)		 Chronic Granulomatous Disease (CGD)
Related terms Granulomatous Disease, Chronic
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov